SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-23-018516
Filing Date
2023-05-22
Accepted
2023-05-22 15:13:02
Documents
59
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1557871
2 ex31-1.htm EX-31.1 19134
3 ex31-2.htm EX-31.2 18994
4 ex32-1.htm EX-32.1 8092
5 ex32-2.htm EX-32.2 7898
  Complete submission text file 0001493152-23-018516.txt   9309444

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE atrx-20230331.xsd EX-101.SCH 48651
7 XBRL CALCULATION FILE atrx-20230331_cal.xml EX-101.CAL 38061
8 XBRL DEFINITION FILE atrx-20230331_def.xml EX-101.DEF 266946
9 XBRL LABEL FILE atrx-20230331_lab.xml EX-101.LAB 400110
10 XBRL PRESENTATION FILE atrx-20230331_pre.xml EX-101.PRE 330673
53 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1474331
Mailing Address P.O. BOX 2161 WAKE FOREST NC 27588
Business Address P.O. BOX 2161 WAKE FOREST NC 27588 919-578-5901
Adhera Therapeutics, Inc. (Filer) CIK: 0000737207 (see all company filings)

IRS No.: 112658569 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-13789 | Film No.: 23944129
SIC: 2834 Pharmaceutical Preparations